EGFR and non-small cell lung carcinoma: In patients with non-small cell lung cancer (NSCLC), those harboring an epidermal growth factor receptor (EGFR) mutation have a higher risk of LMD; specifically 9.4% in EGFR-mutant tumors versus 1.7% in wild-type tumors in a retrospective analysis of patients with NSCLC LMD (9).